Get the Stockscreener App
9.895
3.38%
-0.335
Vir Biotechnology Inc stock is traded at $9.895, with a volume of 543.14K.
It is down -3.38% in the last 24 hours and up +25.28% over the past month.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
See More
Previous Close:
$10.23
Open:
$10.22
24h Volume:
543.14K
Relative Volume:
0.26
Market Cap:
$1.41B
Revenue:
$62.04M
Net Income/Loss:
$-533.34M
P/E Ratio:
-2.5242
EPS:
-3.92
Net Cash Flow:
$-473.07M
1W Performance:
-4.96%
1M Performance:
+25.28%
6M Performance:
+18.94%
1Y Performance:
+9.10%
1-Day Range:
$9.86
$10.65
1-Week Range:
$9.63
$10.67
52-Week Range:
$6.56
$14.45
Vir Biotechnology Inc Stock (VIR) Company Profile
Name
Vir Biotechnology Inc
Sector
Industry
Phone
415-906-4324
Address
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
9.895 | 1.41B | 62.04M | -533.34M | -473.07M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.06 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.00 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.00 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.98 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.70 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-08-23 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-21-23 | Upgrade | Goldman | Neutral → Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-14-22 | Initiated | SVB Leerink | Outperform |
| Sep-09-22 | Initiated | Morgan Stanley | Underweight |
| Mar-03-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Dec-21-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Oct-25-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Jan-27-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-05-20 | Initiated | BofA Securities | Buy |
| Sep-14-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-11-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-20-20 | Initiated | Needham | Buy |
| Mar-19-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-13-20 | Downgrade | Goldman | Buy → Neutral |
| Feb-27-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Feb-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-19 | Initiated | Robert W. Baird | Neutral |
| Nov-05-19 | Initiated | Barclays | Overweight |
| Nov-05-19 | Initiated | Cowen | Outperform |
| Nov-05-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | JP Morgan | Overweight |
View All
Vir Biotechnology Inc Stock (VIR) Latest News
After a year of 7.8% returns, Vir Biotechnology, Inc.'s (NASDAQ:VIR) share price drop last week may have less of an impact on institutional investors - Simply Wall St
HC Wainwright Reiterates Buy Rating for Vir Biotechnology (NASDAQ:VIR) - MarketBeat
Vir Biotechnology, Inc. (NASDAQ:VIR) Short Interest Update - MarketBeat
Vir Biotechnology appoints new Chief Technical Officer By Investing.com - Investing.com Australia
Vir Biotechnology Inc. (VIR) Stock Overview and Recent Developments – Market - HPBL
Vir Biotechnology Shares Surge After Opening Higher: A Market Overview – Market - HPBL
Vir Biotechnology, Inc. Announces Executive Changes -January 30, 2025 at 07:51 am EST - Marketscreener.com
Vir Biotechnology appoints new Chief Technical Officer - Investing.com
Vir Biotechnology Announces Leadership Change in 2025 - TipRanks
Vir Biotechnology Inc. (VIR) Announces CTO Departure - StreetInsider.com
Trading (VIR) With Integrated Risk Controls - Stock Traders Daily
Vir Biotechnology Phase 1 Data on Dual-Masked T-Cell Engagers (TCEs) – Market - HPBL
Vir Biotechnology (NASDAQ:VIR) Shares Down 3.8%Should You Sell? - MarketBeat
Vir Biotechnology (NASDAQ:VIR) Shares Up 6.3%What's Next? - MarketBeat
Why Vir Biotechnology, Inc. (VIR) Is Skyrocketing Now - Insider Monkey
Hepatitis B Virus Infection Clinical and Non-Clinical Studies, - openPR
Vir, Sana gain new modality POC: BioCentury’s Clinical Report - BioCentury
JP Morgan Week 2025 – Marianne De Backer - pharmaphorum
What is Leerink Partnrs’ Forecast for VIR Q1 Earnings? - Defense World
Analysts Set Vir Biotechnology, Inc. (NASDAQ:VIR) PT at $34.83 - Defense World
Vir Biotechnology (NASDAQ:VIR) Shares Down 10.4%Here's What Happened - MarketBeat
Q1 Earnings Estimate for VIR Issued By Leerink Partnrs - MarketBeat
JPMorgan Chase & Co. Has $8.14 Million Stock Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat
Q2 Earnings Estimate for VIR Issued By Leerink Partnrs - MarketBeat
Analysts Set Vir Biotechnology, Inc. (NASDAQ:VIR) Price Target at $34.83 - MarketBeat
Leerink Partners Boosts Vir Biotechnology (NASDAQ:VIR) Price Target to $20.00 - MarketBeat
Nordea Investment Management AB Sells 286,600 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat
Morgan Stanley upgrades Vir Biotechnology to 'overweight,' raises PT to $20 - MSN
Vir Biotech upgraded at Morgan Stanley on cancer drug data - MSN
Vir Biotechnology Catapults 58% On Promising Results In Cancer Treatment - MSN
Morgan Stanley Doubles Vir Biotechnology Price ForecastHere's Why - AOL
Vir Biotechnology (NASDAQ:VIR) Earns "Buy" Rating from HC Wainwright - MarketBeat
VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates - MSN
Morgan Stanley Upgrades Vir Biotechnology (VIR) - MSN
Vir Biotechnology Reports Positive Phase 2 Results, Shares Surge by 58% - GuruFocus.com
Insider Sell: Vicki Sato Sells Shares of Vir Biotechnology Inc (VIR) - GuruFocus.com
Vir Biotechnology: A Rocket Off Phase 1 Data... What Could Go Wrong? (NASDAQ:VIR) - Seeking Alpha
Vir Biotechnology (NASDAQ:VIR) Upgraded by Morgan Stanley to "Overweight" Rating - MarketBeat
Vir Biotechnology (NASDAQ:VIR) Given New $14.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Morgan Stanley upgrades Vir Biotechnology to 'overweight,' raises PT to $20 By Investing.com - Investing.com Canada
Vir Biotechnology Inc Stock (VIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):